CellSeed Inc.
Notice of Revision to Earnings Guidance
Revenue is expected to decline due to delayed revenue recognition for certain projects in the regenerative medicine support business. However, company-wide cost reductions keep operating income flat, and ordinary income and net income attributable to owners of parent are expected to show reduced deficit. The full-year guidance has been revised.
Key Figures
- Net Sales: Previous Forecast 71 million yen → Revised Forecast 50 million yen
- Operating Income: -1,225 million yen (same as previous forecast)
- Ordinary Income: -1,250 million yen → -1,234 million yen
- Net Income Attributable to Owners of Parent: -1,320 million yen → -1,309 million yen
- Net Income per Share: -30.51 yen → -33.81 yen
AI要約
Performance Summary
The earnings guidance for the fiscal year ending December 2026 has been revised. Revenue is expected to decline because revenue recognition for certain projects in the contract regenerative medicine business was deferred. Meanwhile, thorough company-wide cost reductions resulted in operating income remaining in line with the previous forecast, and ordinary income and net income attributable to owners of parent are expected to show narrower deficits.
Outlook and Points to Note
No foreign exchange information is provided, and results may fluctuate depending on future project developments. Note that net income per share has been adjusted from the previous forecast to reflect the exercise status of stock acquisition rights.
CellSeed Inc.
Company overview · Stock price · Financial data · All IR
